A study published Oct. 28, 2026, in Nature found that neutrophils from people with lupus contain many abnormally spliced gene messages that produce new protein pieces. Twenty-one such pieces were found on immune molecules, and patients' T cells and antibodies…
In a phase 2b trial published in NEJM in October 2026, oral icotrokinra led to a clinical response at week 12 in 63% of people with ulcerative colitis at the highest dose vs. 27% with placebo.
In two trials published in NEJM in October 2026, monthly ianalumab lowered Sjögren's disease activity at week 48 slightly more than placebo, but patient-reported symptoms didn't improve more.